Close Menu

NEW YORK (GenomeWeb) – Intermountain Healthcare spinout Navican Genomics today said it closed a $15 million Series A financing round, led by Intermountain.

The financing will go toward the commercialization and expansion of Navican's precision cancer care offering, including the commercialization of its TheraMap solution, which leverages precision genomics, clinical analytics, and patient services for cancer management.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The US Patent and Trademark Office is opening another interference proceeding in the CRISPR patent fight.

There's increasing genetic evidence that a number of ancient hominins may have contributed to the human gene pool, according to Discover's The Crux blog.

The Japan News writes that Japan needs to seize the opportunity to ensure that a wide number of people benefit from personalized cancer treatments.

In Cell this week: messenger RNA expression and translation, RNA localization atlas, and more.